Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis
Authors
Keywords
Ep-ICD, EpCAM, Oral lesion, Dysplasia, Squamous cell carcinoma, Oral cancer, Prognosis
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-07-16
DOI
10.1186/s12885-016-2507-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nuclear Ep-ICD Expression Is a Predictor of Poor Prognosis in “Low Risk” Prostate Adenocarcinomas
- (2015) Jasmeet Assi et al. PLoS One
- Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients
- (2014) Gunjan Srivastava et al. BMC CANCER
- Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences
- (2014) Olivier Gires et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Expression of EpCAMMFand EpCAMMTvariants in human carcinomas
- (2014) Dominic Fong et al. JOURNAL OF CLINICAL PATHOLOGY
- Differential Features of Microsatellite-Unstable Colorectal Carcinomas Depending on EPCAM Expression Status
- (2014) Jung Ho Kim et al. Korean Journal of Pathology
- EpCAM associates with endoplasmic reticulum aminopeptidase 2 (ERAP2) in breast cancer cells
- (2013) Salah-Eldin Gadalla et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis
- (2013) V S Warneke et al. BRITISH JOURNAL OF CANCER
- EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like and HER2 intrinsic subtypes of breast cancer
- (2013) S D Soysal et al. BRITISH JOURNAL OF CANCER
- Expression of Ep-CAM, but not of E48, associates with nodal involvement in advanced squamous cell carcinomas of the larynx
- (2013) Coia Romeu et al. HISTOPATHOLOGY
- Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer
- (2013) Dominic Fong et al. HISTOPATHOLOGY
- S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia
- (2013) Jatinder Kaur et al. INTERNATIONAL JOURNAL OF CANCER
- Context-dependent adaption of EpCAM expression in early systemic esophageal cancer
- (2013) C Driemel et al. ONCOGENE
- Correlation of Tumor Marker Expression with Nodal Disease Burden in Metastatic Head and Neck Cancer
- (2013) Sumita Trivedi et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
- (2012) M. Schmidt et al. ANNALS OF ONCOLOGY
- Expression of cell adhesion molecules and prognosis in breast cancer
- (2012) S. Saadatmand et al. BRITISH JOURNAL OF SURGERY
- Global burden of cancer: opportunities for prevention
- (2012) Ahmedin Jemal LANCET
- Overexpression of Prothymosin Alpha Predicts Poor Disease Outcome in Head and Neck Cancer
- (2011) Satyendra Chandra Tripathi et al. PLoS One
- EpCAM nuclear localization identifies aggressive Thyroid Cancer and is a marker for poor prognosis
- (2010) Ranju Ralhan et al. BMC CANCER
- EpCAM in carcinogenesis: the good, the bad or the ugly
- (2010) B. T. F. van der Gun et al. CARCINOGENESIS
- Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)
- (2010) K. El-Sahwi et al. MOLECULAR CANCER THERAPEUTICS
- Nuclear and Cytoplasmic Accumulation of Ep-ICD Is Frequently Detected in Human Epithelial Cancers
- (2010) Ranju Ralhan et al. PLoS One
- Identification of EpCAM as a Molecular Target of Prostate Cancer Stroma
- (2009) Sumana Mukherjee et al. AMERICAN JOURNAL OF PATHOLOGY
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
- (2009) M. Schmidt et al. ANNALS OF ONCOLOGY
- Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases
- (2009) Ashley Cimino et al. BREAST CANCER RESEARCH AND TREATMENT
- EpCAM: Another Surface-to-Nucleus Missile
- (2009) Graham Carpenter et al. CANCER CELL
- The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
- (2009) M. Munz et al. CANCER RESEARCH
- Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer
- (2009) Anthony L.A. Fields et al. JOURNAL OF CLINICAL ONCOLOGY
- Nuclear signalling by tumour-associated antigen EpCAM
- (2009) Dorothea Maetzel et al. NATURE CELL BIOLOGY
- Discovery and Verification of Head-and-neck Cancer Biomarkers by Differential Protein Expression Analysis Using iTRAQ Labeling, Multidimensional Liquid Chromatography, and Tandem Mass Spectrometry
- (2008) Ranju Ralhan et al. MOLECULAR & CELLULAR PROTEOMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now